PBE

Invesco Biotechnology & Genome ETF

USD

Set alert

Price alert · PBE

All alert types
102.50 USD -0.96 -0.93%
As of Oct 30, 2026 Extended hours 102.50 0.00%
Bid
102.02 × 200
Ask
102.76 × 400
102.29 Day range 104.24
73.22 52-week range 103.46
YTD
+24.77%
1 year
+39.99%
Open
103.47
Prev close
103.46
Mkt cap
315.42M
Vol
13.14K
Avg vol
30.18K
EPS
3.66
P/E
27.98
Div yield
0.00%
More statistics
Low
102.29
High
104.24
Forward P/E
0.00
Beta
0.00
Short ratio
0.00
Dividend
0.00
Ex-div date
50-d avg
69.17
200-d avg
67.04

5D chart

Chart tools
Interval

Chart is warming up

The five-day price history for PBE has not been loaded yet. Try again in a moment.

Discussion (1)

Sign in to join the discussion

VICKY HANUKA PBE 3 years ago #1

$PTC Therapeutics(PTCT.US)$ ?????????????? Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi -- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.